MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$724,931K
(-35.31%↓ Y/Y)
Net loss
attributable to redeemable...
-$8,007K
(-5.56%↓ Y/Y)
Net loss
-$732,938K
(-34.89%↓ Y/Y)
Loss before income
taxes
-$732,503K
(-35.10%↓ Y/Y)
Provision for income taxes
$435K
(-62.27%↓ Y/Y)
Product
$362,368K
License And Service
$128,322K
Royalty
$11,386K
Loss from operations
-$523,411K
(11.73%↑ Y/Y)
Total other income
(expense), net
-$209,092K
(-511.77%↓ Y/Y)
Total revenues, net
$502,076K
(126.26%↑ Y/Y)
Other income, net
$43,058K
(250.86%↑ Y/Y)
Interest income
$19,854K
(15.10%↑ Y/Y)
Total operating costs
and expenses
$1,025,487K
(25.85%↑ Y/Y)
Noncash interest
expense on deferred...
$125,138K
Net loss from equity
method investments
-$72,608K
(-132.84%↓ Y/Y)
Interest expense
$53,103K
(-46.52%↓ Y/Y)
Loss on
extinguishments of debt
-$21,155K
(20.44%↑ Y/Y)
Selling, general and
administrative
$531,225K
(83.86%↑ Y/Y)
Research and development
$451,953K
(-10.76%↓ Y/Y)
Restructuring, impairment, and
related charges
$21,347K
Total cost of revenues
$20,962K
(440.54%↑ Y/Y)
Product
$15,687K
License Services And
Royalty
$5,275K
Back
Back
Income Statement
source: myfinsight.com
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)